141 related articles for article (PubMed ID: 27924664)
1. Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.
Liu X; Fiocco M; Swen JJ; Guchelaar HJ
Acta Oncol; 2017 Apr; 56(4):582-589. PubMed ID: 27924664
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
3. Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.
Akaza H; Naito S; Ueno N; Aoki K; Houzawa H; Pitman Lowenthal S; Lee SY
Jpn J Clin Oncol; 2015 Jun; 45(6):576-83. PubMed ID: 25917359
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
Yoo C; Kim JE; Lee JL; Ahn JH; Lee DH; Lee JS; Na S; Kim CS; Hong JH; Hong B; Song C; Ahn H
Jpn J Clin Oncol; 2010 Oct; 40(10):980-5. PubMed ID: 20457723
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Kim HR; Park HS; Kwon WS; Lee JH; Tanigawara Y; Lim SM; Kim HS; Shin SJ; Ahn JB; Rha SY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):825-35. PubMed ID: 24013576
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.
Lee SH; Bang YJ; Mainwaring P; Ng C; Chang JW; Kwong P; Li RK; Sriuranpong V; Toh CK; Yuan J; Pitman Lowenthal S; Chung HC
Asia Pac J Clin Oncol; 2014 Sep; 10(3):237-45. PubMed ID: 24576311
[TBL] [Abstract][Full Text] [Related]
10. Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years.
Miyake H; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2018 Jun; 38(6):3593-3599. PubMed ID: 29848715
[TBL] [Abstract][Full Text] [Related]
11. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.
Miyake H; Miyazaki A; Harada K; Fujisawa M
Med Oncol; 2014 Jun; 31(6):978. PubMed ID: 24793747
[TBL] [Abstract][Full Text] [Related]
12. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Chu YH; Li H; Tan HS; Koh V; Lai J; Phyo WM; Choudhury Y; Kanesvaran R; Chau NM; Toh CK; Ng QS; Tan PH; Chowbay B; Tan MH
PLoS One; 2015; 10(8):e0134102. PubMed ID: 26244574
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Donskov F; Michaelson MD; Puzanov I; Davis MP; Bjarnason GA; Motzer RJ; Goldstein D; Lin X; Cohen DP; Wiltshire R; Rini BI
Br J Cancer; 2015 Dec; 113(11):1571-80. PubMed ID: 26492223
[TBL] [Abstract][Full Text] [Related]
14. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
[TBL] [Abstract][Full Text] [Related]
15. Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.
Vrdoljak E; Géczi L; Mardiak J; Ciuleanu TE; Leyman S; Zhang K; Sajben P; Torday L
Pathol Oncol Res; 2015 Jul; 21(3):775-82. PubMed ID: 25557271
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Mir MH; Changal KH; Aziz SA; Bhat GM; Lone AR
Int Urol Nephrol; 2016 Nov; 48(11):1811-1816. PubMed ID: 27448573
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma patients in Egypt.
Edesa WA; Abdelmalek RR
Asian Pac J Cancer Prev; 2015; 16(5):1971-6. PubMed ID: 25773796
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S; Iacovelli R; Boni L; Rizzo M; Derosa L; Rossi M; Galli L; Procopio G; Sisani M; Longo F; Santoni M; Morelli F; Di Lorenzo G; Altavilla A; Porta C; Camerini A; Escudier B;
Ann Oncol; 2015 Oct; 26(10):2107-13. PubMed ID: 26216384
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]